Stay updated with breaking news from Anne Kerber. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Bristol Myers announces that KRAZATI in combination with cetuximab demonstrates clinically meaningful activity as a targeted treatment option for patients with previously treated locally advanced or...
Late-breaking data to be featured in an oral presentation at the American Association for Cancer Research annual meeting on Monday, April 8 and highlighted as part of the official meeting press...
Approval by European Commission would expand Reblozyl’s indication to include first-line treatment of anemia in adults with MDS in Europe In the pivotal Phase 3 COMMANDS study, Reblozyl nearly...
Luspatercept has been recommended for approval by the EMA for patients with transfusion-dependent anemia and lower-risk myelodysplastic syndromes.
The Food and Drug Administration granted a priority review to Krazati plus Erbitux for KRAS G12C-mutant locally advanced or metastatic colorectal cancer.